Interestingly, high-dose HVEM-Fc did not exhibit anti-tumor activity, suggesting that simultaneous engagement of both BTLA and LIGHT at high doses may diminish or even reverse the anti-tumor effect. The gene discussed is TNFSF14; the disease is neoplasm.